cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) (PDE4D)

cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) is a member of the phosphodiesterase family responsible for the hydrolysis of the second messenger cyclic adenosine monophosphate (cAMP) [UniProt: Q08499]. By regulating the localized concentrations of cAMP, PDE4D plays a critical role in modulating signal transduction pathways involved in inflammation, smooth muscle relaxation, and cognitive processes [NCBI Gene: 5144]. In the central nervous system, PDE4D is highly expressed in regions associated with memory and learning, making it a target for treating neurodegenerative and neurodevelopmental disorders like Alzheimer's and Fragile X syndrome [PubMed: 24713611]. In the periphery, it is involved in the inflammatory response of leukocytes and the tone of airway smooth muscle, relevant to respiratory diseases like asthma and COPD [PubMed: 4055331]. While pan-PDE4 inhibitors are clinically used for inflammatory conditions, they are often limited by gastrointestinal side effects like nausea and vomiting, which are specifically linked to PDE4D inhibition in the area postrema [PubMed: 24713611]. Current drug development efforts focus on allosteric or isoform-selective inhibitors to enhance cognitive benefits while minimizing these systemic adverse effects [ClinicalTrials.gov: NCT05358886].

Other names

PDE4DDPDE3STRK1HSPDE4D3Phosphodiesterase 4D

Inhibition of the enzyme prevents the hydrolysis of cAMP to 5'-AMP, leading to elevated intracellular cAMP levels and activation of protein kinase A (PKA) and cAMP-response element-binding protein (CREB) pathways.